Acrivon Therapeutics, Inc. — Form D
Acrivon Therapeutics, Inc. of Watertown, MA, a company, filed a Form D exempt-offering notice with the SEC on 2021-11-23. The offering totals $100.0M, of which $100.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-11-23
- Form: D
- Accession: 0001781174-21-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $100.0M
- Amount sold: $100.0M
- Investors: 13
- Date of first sale: 2021-11-09
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-422273
Issuer
- Name: Acrivon Therapeutics, Inc.
- CIK: 0001781174
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 480 Arsenal Way, Watertown, MA, 02472
- Phone: 617-207-8979
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Peter Blume-Jensen | Director | Watertown, MA |
| Marcin Czernik | Director | Watertown, MA |
| Derek DiRocco | Director | Boston, MA |
| Kristina Masson | Director | Watertown, MA |
| Sharon Shacham | Director | TEL AVIV, L3 |
| Peter Blume-Jensen | Executive Officer | Watertown, MA |
| Eric Devroe | Executive Officer | Watertown, MA |
| Erick Gamelin | Executive Officer | North Hollywood, CA |
| Kristina Masson | Executive Officer | Watertown, MA |
Other filings by this issuer (1)
More